Pro Share Advisors LLC C4 Therapeutics, Inc. Transaction History
Pro Share Advisors LLC
- $42.5 Billion
- Q4 2024
A detailed history of Pro Share Advisors LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 20,283 shares of CCCC stock, worth $37,320. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,283
Previous 11,079
83.08%
Holding current value
$37,320
Previous $63,000
15.87%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CCCC
# of Institutions
125Shares Held
62.7MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$12.8 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$12.6 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$11.2 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$8.98 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$8.37 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $90M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...